BOSTON, Dec. 11, 2019 /PRNewswire/ --Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced positive, initial ex-vivo results of PTI's proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulators, PTI-801, PTI-808, and PTI-428, in individuals with CF who are ineligible for the current standard of care CFTR modulator therapies due to their genotype. The data are part of a pan-European strategic initiative, known as HIT-CF (Human Individualized Therapy of CF), which seeks to accelerate the development of, and access to, personalized therapies for CF patients, beginning with those for whom no currently approved CFTR modulator therapy is indicated.
HIT-CF is sponsored by the European Commission Horizon 2020 program, in which CF-Europe, a patient organization representing more than 48,000 individuals with CF, collaborates and with the European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN), which is recruiting adult CF patients into the ex- vivo study through its 43 clinical trial centers. HIT-CF collects tissue samples from CF patients and develops organoids, or miniaturized organs, that are genetically identical to the patient donor, and share the same micro-anatomy as the organ from which they were derived.
As of today, rectal organoids from over 300 subjects have been collected for functional profiling and of those, 65 have been tested for response to PTI's investigational drugs. Early results support the initiation of enrollment of responding subjects into HIT-CF's clinical trial known as "CHOICES" (Crossover trial based on Human Organoid Individual response in CF - Efficacy Study), which is designed to evaluate the translation of organoid ex-vivo response to potential clinical benefit, such as changes in FEV1 and sweat chloride. CHOICES, which is expected to initiate in mid-2020, will be the first ever personalized medicine-based study in CF, with initial data expected by the end of 2020. Fully funded by the HIT-CF, this trial is a placebo controlled, double blind, crossover study with an 8-week treatment period and 6 months of uninterrupted dosing. The results may serve as the basis for a potential Marketing Authorization Application with the European Medicines Agency (EMA) in 2021 through a novel regulatory pathway which is being pursued jointly by Proteostasis and HIT-CF. The CHOICES clinical study is part of PTI's broader clinical development strategy for its CFTR modulator candidates that is already separately funded for the common genotypes.
Results from the HIT-CF project to date will be presented at the Keystone Symposia on Tissue Organoids titled "Tissue Organoids as Models of Host Physiology and Pathophysiology of Disease (J1)" taking place on January 19-23, 2020 in Vancouver, BC, Canada.
"Proteostasis is honored to have been invited to participate in the HIT-CF project and is the only company in the group with a combination of novel CFTR modulators being tested ex-vivo. We are very enthusiastic about the progress of the study," said Geoffrey Gilmartin, M.D., M.M.Sc., Chief Medical Officer of Proteostasis Therapeutics. "In Europe alone, there are more than 2,300 adult patients whose genotypes render them ineligible for approved CFTR modulators and exclude them from participating in clinical trials with this drug class. This project's proposed personalized medicine approach is paving a potential new way to develop and provide access to novel CFTR modulators for patients with the most dire need for treatment options that target the cause of the disease. Additionally, based on an individual patient's disease phenotype and not just the genetic designation, this approach could also create a new path towards more effective treatment for all people with CF."
"The inequality in access to CFTR modulators is an acute problem across Europe where 1 in 5 individuals do not have a F508del mutation. In addition, drug reimbursement policies are leading to an ever-growing gap between patients who do, and those who do not have effective treatment options," said Christiane De Boeck, Work Package Leader at HIT-CF, and Former President of ECFS. "At HIT-CF Europe, we believe that novel strategies such as personalized medicine and development of new treatment options are central to addressing the inequality of access across the continent. We are thrilled with these initial results and look forward to providing additional updates."
About Organoids
Organoids are cell cultures that grow in a culture dish and look similar to the organ from which they are derived. Because organoids are made from stem cells, they contain the same mutations as the person from whom the biopsies are derived. Investigational drugs which target the basic defect of CF can be used in an organoid system to evaluate rare mutations where the drugs may have a positive effect.
Unlike in vitro systems such as human bronchial epithelial (HBE) cells, which are derived from lungs that have been removed from CF patients, or the engineered, rat-derived FRT cell line, the latter has resulted in false positive clinical results, rectal organoids are cultured from tissues obtained through a minimally invasive and painless procedure from donors who then become eligible to participate in a clinical study. Organoids can provide valuable insights for donors, including their likelihood of achieving improvements in pulmonary function and reductions in sweat chloride concentration with CFTR modulators based on the ex-vivo response to those drugs.1
About HIT-CF Europe
HIT-CF Europe is a research project which aims to provide better treatment and better lives for people with cystic fibrosis (CF) and rare mutations. To achieve this, drug candidates are first tested on patient-derived organoids in qualified laboratories across Europe. Subsequently, based on the measured signal in the organoids, a smaller group of patients will be invited to participate in a clinical trial with one or more investigational molecules from a participating pharmaceutical company.
All participating centers are part of the European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN). The project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement number 755021. For more information, visit http://www.hitcf.org.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. For more information, visit http://www.proteostasis.com.
Safe Harbor
To the extent that statements in this release are not historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "aim," "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements made in this release include, without limitation, statements regarding the expected presentation at an upcoming conference. Forward-looking statements made in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Such risks and uncertainties include, without limitation, our expectations regarding our participation in HIT-CF's pan-European strategic initiative,the potential of our proprietary combination therapies for the treatment of CF, the potential benefit of our proprietary combination therapies to patients, expected timing of patient enrollment in, data from, the completion of, and reporting top line results of our clinical studies and cohorts for our clinical programs, including our planned Phase 2 program and initiation of a pivotal or registrational study, the possibility final or future results from our drug candidate trials (including, without limitation, longer duration studies) do not achieve positive results or are materially and negatively different from or not indicative of the preliminary results reported by the Company (noting that these results are based on a small number of patients and small data set), uncertainties inherent in the execution and completion of clinical trials (including, without limitation, the possibility that FDA or other regulatory agency comments delay, change or do not permit trial commencement, or intended label, or the FDA or other regulatory agency requires us to run cohorts sequentially or conduct additional cohorts or pre-clinical or clinical studies), in the enrollment of CF patients in our clinical trials in a competitive clinical environment, in the timing of availability of trial data, in the results of the clinical trials, in possible adverse events from our trials, in the actions of regulatory agencies, in the endorsement, if any, by therapeutic development arms of CF patient advocacy groups (and the maintenance thereof), in the commercialization and acceptance of new therapies, and those set forth in our Annual Report on Form 10-K for the year ended December 31, 2018, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and our other SEC filings. We assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACTS:
Investors: David Pitts / Claudia StyslingerArgot Partners212.600.1902 david@argotpartners.com/ claudia@argotpartners.com
Media:David RosenArgot Partners212.600.1902david.rosen@argotpartners.com
1Berkers et al, Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis Cell Reports 26, 17011708,February 12, 2019
SOURCE Proteostasis Therapeutics, Inc.
Read the original post:
Proteostasis Therapeutics to Initiate First Ever Personalized Medicine-Based Clinical Trial, CHOICES, in European CF Patients with Genotypes...
- Congress Gives Stem Cells Another Shot -ASK THE EXPERT- ... [Last Updated On: August 4th, 2011] [Originally Added On: August 4th, 2011]
- Stem Cell Game 3- Grow with the Flow [Last Updated On: August 5th, 2011] [Originally Added On: August 5th, 2011]
- PROSTATE CANCER and stem cells [Last Updated On: August 13th, 2011] [Originally Added On: August 13th, 2011]
- Preview: 21st Century Snake Oil [Last Updated On: September 2nd, 2011] [Originally Added On: September 2nd, 2011]
- Stem cells: the future of medicine? [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Stem Cells: Politics vs. Medicine [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Mesenchymal Stem Cells in Regenerative Medicine: Of Hopes and Challenges [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- An amazing story of stem cells, regenerative medicine and healing power: [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- Preserving Stem Cells: Regenerative Medicine [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- TEDxPhoenix - Jane Maienschein - Stem Cells, Regenerative Medicine and Us [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- Personalized Medicine: Stem Cells 1/2 [Last Updated On: September 14th, 2011] [Originally Added On: September 14th, 2011]
- A Century of Stem Cells - Johns Hopkins Medicine [Last Updated On: September 16th, 2011] [Originally Added On: September 16th, 2011]
- What are stem cells? How can they be used for medical benefit? [Last Updated On: September 17th, 2011] [Originally Added On: September 17th, 2011]
- STEM CELLS TRANSLATIONAL MEDICINE Official Announcement [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- Turning Adult Stem Cells into Medicine - Zannos Grekos, MD [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- A New Era in Regenerative Medicine [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Bruce Conklin: Drug screening with stem cells [Last Updated On: September 27th, 2011] [Originally Added On: September 27th, 2011]
- Professors Chandran and ffrench-constant - Are stem cells the future of regenerative medicine? [Last Updated On: September 27th, 2011] [Originally Added On: September 27th, 2011]
- Hormone Myths vs. Medical Literature and How to Grow Your Own Stem Cells - Ronald Rothenberg, MD [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- Cardiovascular Derivatives of Embryonic Stem Cells in Cardiac Repair and Drug Discovery [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- Jackson Laboratory symposium: What's vital for effective stem cell therapies? [Last Updated On: September 30th, 2011] [Originally Added On: September 30th, 2011]
- Alzheimer's Disease: Spotlight on Stem Cell Research - Rod Shankle [Last Updated On: October 3rd, 2011] [Originally Added On: October 3rd, 2011]
- "StemEnhance" the Biggest Scientific [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Stem cell medical breakthrough? [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- The Future of Stem Cells and Regenerative Medicine [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Stem Cell Clinical Trials : University of Miami Miller School of Medicine [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Medical tourism in Croatia - Regenerative medicine-Stem cells in reconstructive surgery [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Bioethics Stem Cells and the New Biology [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- Stem Cells: The Hope The Hype and the Science [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- Skin Stem Cells: Their Biology [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Spotlight on Cancer Stem Cell Research [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Rationale [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Sickle Cell Anemia: Stem Cell Gene Therapy - Donald Kohn [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Stem Cells and Parkinson's Disease [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Stem Cell Research: Macular Degeneration [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- An amazing story of stem cells and regenerative medicine [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Stem Cell City - Lisa Ray [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Stem Cell Therapy: Healing Force of the future [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Adult Stem Cells in Drug Discovery and Therapeutics [Last Updated On: October 7th, 2011] [Originally Added On: October 7th, 2011]
- Medical Breakthrough: First Stem Cell Procedure [Last Updated On: October 7th, 2011] [Originally Added On: October 7th, 2011]
- Dr. Judith Oppenheim, Chicago on Dental Stem Cells on WGN-TV's Medical Watch. [Last Updated On: October 9th, 2011] [Originally Added On: October 9th, 2011]
- Jerome Zack: Creating iPS Cells - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- Sight for sore eyes - Video [Last Updated On: October 15th, 2011] [Originally Added On: October 15th, 2011]
- Regenerative Medicine Update: Stem Cells and Functional Testing - Mitchell J. Ghen, DO, PhD - Video [Last Updated On: October 15th, 2011] [Originally Added On: October 15th, 2011]
- Stem cells as the future of medicine - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- Neural Stem Cells Reverse Alzheimer's-Like Symptoms - Video [Last Updated On: October 19th, 2011] [Originally Added On: October 19th, 2011]
- Deafness: Spotlight on Stem Cell Research - Ebenezer Yamoah - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- Leukemia: Spotlight on Stem Cell Research - Patient Stories - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- Epidermolysis Bullosa: Corrected iPS Stem Cell-Based Therapy - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- iPS Stem Cell-Based Treatment of Epidermolysis Bullosa - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- Parkinson's Disease: Spotlight on Stem Cell Research - Arnold Kriegstein - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- Closing Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine - Video [Last Updated On: October 23rd, 2011] [Originally Added On: October 23rd, 2011]
- The Sue and Bill Gross Stem Cell Regenerative Medicine Center at UCI - Video [Last Updated On: October 26th, 2011] [Originally Added On: October 26th, 2011]
- Stem Cell Institute - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- StemCellTV Special Report - Stem Cell Therapy a "Medical Game Changer" - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- Adult Stem Cells and Regeneration - Video [Last Updated On: November 8th, 2011] [Originally Added On: November 8th, 2011]
- Cloned Embryonic Stem Cells, FIRST (Brainstorm Ep26) - Video [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- Beating Heart Stem Cells - Video [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- Stem Cell Research In Toronto - Video [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- Stem Cells and Their Amazing Potential 2011 trailer - Video [Last Updated On: November 15th, 2011] [Originally Added On: November 15th, 2011]
- Stemcell Research and Aging - Panel 1 - Video [Last Updated On: December 13th, 2011] [Originally Added On: December 13th, 2011]
- Austin Forum - Nov 1st (Part 4 of 4) - Video [Last Updated On: December 13th, 2011] [Originally Added On: December 13th, 2011]
- Vet-Stem Medistem Cellmedicine Rheumatoid Arthritis Stem Cell Video - Video [Last Updated On: December 19th, 2011] [Originally Added On: December 19th, 2011]
- Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video [Last Updated On: December 26th, 2011] [Originally Added On: December 26th, 2011]
- Stem Cell-Derived Heart Cells: Bruce Conklin - CIRM Science Writer's Seminar - Video [Last Updated On: January 5th, 2012] [Originally Added On: January 5th, 2012]
- Pope gives support to adult stem cells and asks for ethics in scientific research - Video [Last Updated On: January 5th, 2012] [Originally Added On: January 5th, 2012]
- Stem Cell Treatment for Rheumatoid Arthritis - Darnell Morris - Video [Last Updated On: January 5th, 2012] [Originally Added On: January 5th, 2012]
- Personalized Medicine: Stem Cells 2/2 - Video [Last Updated On: January 13th, 2012] [Originally Added On: January 13th, 2012]
- Utilizing Stem Cell-derived Cardiomyocytes for Early Safety Screening - Webinar Presentation - Video [Last Updated On: January 22nd, 2012] [Originally Added On: January 22nd, 2012]
- Stem Cell Stage Bypassed in Skin Cell to Brain Cell Transformation [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- Encouraging Results with Stem Cell Transplant for Brain Injury [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- Stem cell injection successfully treats urinary incontinence [Last Updated On: February 13th, 2012] [Originally Added On: February 13th, 2012]
- ImmunoCellular Therapeutics To Present at Targeting Stem Cells Symposium during 19th Annual Molecular Medicine Tri ... [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- Adult Stem Cell Success Stories - Barry Goudy - Video [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- Stem Cell Treatment for T-6 Spinal Cord Injury - Video [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- Stem Cells China-Switzerland.wmv - Video [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- Stem cell find offers hope for infertility [Last Updated On: February 27th, 2012] [Originally Added On: February 27th, 2012]
- Stem cell fertility treatments could be risky for older women [Last Updated On: February 28th, 2012] [Originally Added On: February 28th, 2012]
- A*STAR Scientists Make Groundbreaking Discovery on Stem Cell Regulation [Last Updated On: March 1st, 2012] [Originally Added On: March 1st, 2012]
- UGA study reveals basic molecular 'wiring' of stem cells [Last Updated On: March 1st, 2012] [Originally Added On: March 1st, 2012]